Home › Compare › BCCOY vs EQR

BCCOY vs EQR: Dividend Comparison 2026

BCCOY yields 533.33% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BCCOY wins by $101500.18M in total portfolio value
10 years
BCCOY
BCCOY
● Live price
533.33%
Share price
$0.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$101500.22M
Annual income
$74,150,491,507.64
Full BCCOY calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — BCCOY vs EQR

📍 BCCOY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBCCOYEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BCCOY + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BCCOY pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BCCOY
Annual income on $10K today (after 15% tax)
$45,333.33/yr
After 10yr DRIP, annual income (after tax)
$63,027,917,781.49/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, BCCOY beats the other by $63,027,914,534.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BCCOY + EQR for your $10,000?

BCCOY: 50%EQR: 50%
100% EQR50/50100% BCCOY
Portfolio after 10yr
$50750.13M
Annual income
$37,075,247,663.62/yr
Blended yield
73.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

BCCOY
No analyst data
Altman Z
-2.5
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BCCOY buys
0
EQR buys
0
No recent congressional trades found for BCCOY or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBCCOYEQR
Forward yield533.33% ✓4.73%
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$101500.22M ✓$40.5K
Annual income after 10y$74,150,491,507.64 ✓$3,819.61
Total dividends collected$99158.23M ✓$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BCCOY vs EQR ($10,000, DRIP)

YearBCCOY PortfolioBCCOY Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$64,033$53,333.33$11,248$547.57+$52.8K → BCCOY
2$387,685$319,169.26$12,701$666.53+$375.0K → BCCOY
3$2,220,791$1,805,968.17$14,405$814.59+$2.21M → BCCOY
4$12,044,657$9,668,410.74$16,413$999.84+$12.03M → BCCOY
5$61,894,777$49,006,993.47$18,795$1,232.92+$61.88M → BCCOY
6$301,588,053$235,360,641.70$21,639$1,527.95+$301.57M → BCCOY
7$1,394,490,436$1,071,791,219.76$25,057$1,903.80+$1394.47M → BCCOY
8$6,123,670,416$4,631,565,648.90$29,197$2,385.87+$6123.64M → BCCOY
9$25,560,497,666$19,008,170,321.16$34,250$3,008.70+$25560.46M → BCCOY
10$101,500,224,010$74,150,491,507.64$40,467$3,819.61+$101500.18M → BCCOY

BCCOY vs EQR: Complete Analysis 2026

BCCOY — Stock

BICO Group AB (publ) operates as a bio convergence company in North America, Europe, Asia, and internationally. It operates through two segments, Laboratory Solutions and Bioautomation. The Laboratory Solutions segment offers 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments, as well as services and related consumables, such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues for applications in regulatory testing. This segment also offers services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharmaceutical and biotechnology companies. The Bioautomation segment offers products in precision dispensing and biosensor technology to the industrial customer; and diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. In addition, it offers core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions. It primarily serves medical, pharmaceutical, and cosmetic industries. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was founded in 2016 and is based in Gothenburg, Sweden.

Full BCCOY Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this BCCOY vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BCCOY vs SCHDBCCOY vs JEPIBCCOY vs OBCCOY vs KOBCCOY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.